| Synonyms: | |
| Status: | Approved |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| UNII: | 99YXE507IL |
| InChI Key | SGOIRFVFHAKUTI-ZCFIWIBFSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C9H14N5O4P |
| Molecular Weight | 287.22 |
| AlogP | -0.05 |
| Hydrogen Bond Acceptor | 7.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 136.38 |
| Molecular species | ACID |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 19.0 |
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Bone Diseases, Metabolic | Phase 4 | ClinicalTrials |
| HIV Infections | Phase 4 | ClinicalTrials |
| Acquired Immunodeficiency Syndrome; Communicable Diseases; HIV Infections; Infection | Phase 4 | ClinicalTrials |
| HIV Infections | Phase 1 | ClinicalTrials |
| Acquired Immunodeficiency Syndrome; HIV Infections; Immunologic Deficiency Syndromes | Phase 3 | ClinicalTrials |
| Acquired Immunodeficiency Syndrome; HIV Infections; Immunologic Deficiency Syndromes | Phase 4 | ClinicalTrials |
| Syphilis | Phase 4 | ClinicalTrials |
| HIV Infections | Phase 3 | ClinicalTrials |
| HIV Infections | Phase 4 | ClinicalTrials |
| HIV Infections | Phase 3 | ClinicalTrials |
| HIV Infections | Phase 2 | ClinicalTrials |
| Hepatitis; Hepatitis B | Phase 2 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 147127-20-6 |
| ChEBI | 63625 |
| ChEMBL | CHEMBL483 |
| DrugBank | DB00300 |
| DrugCentral | 2592 |
| EPA CompTox | DTXSID9040132 |
| FDA SRS | 99YXE507IL |
| Human Metabolome Database | HMDB14445 |
| Guide to Pharmacology | 10948 |
| PDB | TFO |
| PharmGKB | PA10204 |
| PubChem | 464205 |
| SureChEMBL | SCHEMBL39724 |
| ZINC | ZINC000001543475 |
| CAS NUMBER | 147127-20-6 |
| ChEBI | 63625 |
| ChEMBL | CHEMBL3989702 |
| DrugBank | DB00300 |
| FDA SRS | 99YXE507IL |
| Human Metabolome Database | HMDB14445 |
| Guide to Pharmacology | 10948 |
| PDB | TFO |
| PubChem | 464205 |
| SureChEMBL | SCHEMBL39724 |